チゲサイクリン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H319：強い眼刺激

  H372：長期にわたる、または反復暴露により臓器の障 害

  H410：長期的影響により水生生物に非常に強い毒性

• 注意書き

  P202：全ての安全注意を読み理解するまで取り扱わないこ と。

  P260：粉じん/煙/ガス/ミスト/蒸気/スプレーを吸入しないこ と。

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P273：環境への放出を避けること。

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

  P308+P313：暴露または暴露の懸念がある場合：医師の診断/手当てを 受けること。

チゲサイクリン 価格

チゲサイクリン 化学特性,用途語,生産方法

• 外観

  うすい黄色～黄赤色, 結晶性粉末～粉末

• 用途

  グリシルサイクリン系抗生物 質です。リボソーム 30S に結合し、タンパク 質合成阻害作用を示します。テトラサイクリ ン系とは異なる部位に結合します。

• 効能

  抗生物質, タンパク質合成阻害薬

• 商品名

  タイガシル (ファイザー)

• 説明

  The emergence of drug-resistant bacteria has diminished the clinical utility of the tetracyclines. Research to circumvent the efflux and ribosomal protection mechanisms of bacteria has led to the development of the glycylcyclines. Tigecycline is the first glycylcycline antibiotic to launch for the parenteral treatment of baterial infection, including complicated intra-abdominal and skin infections. Its mechanism of action involves inhibiting protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome to effectively prevent incorporation of amino acid residues into elongating peptide chains. Presumably, ribosomal protection proteins are ineffective against tigecycline due to its higher affinity for ribosomal binding compared to tetracyclines (approximately 16-fold). In addition, tigecycline may be resistant to efflux mechanisms by either their inability to translocate it across the cytoplasmic membrane due to steric complications or simply by their failure to recognize the molecule.
  

• 化学的特性

  Orange Solid

• 使用

  Tigecycline is a semi-synthetic tetracycline prepared by the introduction of a tert-butylaminoacetamido group into a previously unexplored and un-substituted region of existing tetracyclines. Like other tetracyclines, tigecycline acts by reversibly binding to the 30S ribosomal subunit and inhibits protein translation by blocking entry of aminoacyl-tRNA into the ribosome A site. The enhanced activity can be attributed to stronger binding affinity, thus minimising the impact of existing mechanisms of resistance. Tigecycline is regarded as the first of a new class of glycylcyline antibiotics. Critical comparison to the tetracycline class appears to be lacking in the literature.

• 定義

  ChEBI: Tetracycline in which the hydroxy group at position 5 and the methyl group at position 6 are replaced by hydrogen, and with a dimethylamino substituent and an (N-tert-butylglycyl)amino substituent at positions 7 and 9, respe tively. A glycylcycline antibiotic, it has activity against a broad range of Gram-positive and Gram-negative bacteria, including tetracycline-resistant organisms. It is used for the intravenous treatment of complicated skin and skin structure infections ca sed by susceptible organisms.

• 抗菌性

  It is as potent as, or more potent than, earlier tetracyclines and activity is retained against strains expressing acquired tetracycline resistance determinants. It displays better activity than tetracycline, doxycycline or minocycline against Streptococcus spp. and against Enterococcus faecalis and E. faecium. Among Gram-negative organisms it displays improved activity against Citrobacter freundii, Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, Salmonella spp., Serratia marcescens and Shigella spp. The spectrum includes rapidly growing mycobacteria. Ps. aeruginosa, Pr. mirabilis, other Proteus spp. and some strains of Corynebacterium jeikeium are resistant. Activity against strains expressing acquired resistance to earlier tetracyclines is attributed to failure of the MFS efflux pumps to recognize tigecycline, and to a novel mechanism of ribosome binding that permits tigecycline to overcome ribosomal protection mechanisms.
  Comparative susceptibility data for some atypical pathogens are not available. However, in common with earlier tetracyclines, it is active against Chlamydophila and Mycoplasma spp. and rapidly growing Mycobacteria spp. It is less active than minocycline or tetracycline against U. urealyticum.

• 一般的な説明

  Tigecycline (Tygacil) is a first-in-class (a glycylcycline) intravenousantibiotic that was designed to circumvent manyimportant bacterial resistance mechanisms. It is not affectedby resistance mechanisms such as ribosomal protection, effluxpumps, target site modifications, β-lactamases, or DNAgyrase mutations. Tigecycline binds to the 30S ribosomalsubunit and blocks peptide synthesis. The glycylcyclinesbind to the ribosome with five times the affinity of commontetracyclines. Tigecycline also possesses a novel mechanismof action, interfering with the mechanism of ribosomal protectionproteins. Tigecycline, unlike common tetracyclines,is not expelled from the bacterial cell by efflux pumpingprocesses.
  Tigecycline is recommended for the treatment of complicatedskin and skin structure infections caused by E. coli,E. faecalis (vancomycin-susceptible isolates), S. aureus(methicillin-susceptible and methicillin-resistant isolates),S. pyogenes, and B. fragilis among others. Tigecycline is alsoindicated for complicated intra-abdominal infections causedby strains of Clostridium, Enterobacter, Klebsiella, andBacteroides. To reduce the development of resistance to tigecycline,it is recommended that this antibiotic be used onlyfor those infections caused by proven susceptible bacteria.Glycylcyclines are structurally similar to tetracyclines,and appear to have similar adverse effects. These mayinclude photosensitivity, pancreatitis, and pseudotumorcerebri. Nausea and vomiting have been reported.

• 応用例（製薬）

  9-T-butylglycylamido-minocycline. A compound of the glycylcycline class available as a powder for intravenous infusion.

• 薬物動態学

  C_max 100 mg intravenous infusion (1 h): 0.85–1 mg/L
  Plasma half-life: 37–67 h
  Volume of distribution: 7–10 L/kg
  Plasma protein binding: 68%
  Distribution and excretion
  It is widely distributed and is concentrated in the gallbladder, colon and lung. The volume of distribution is dose related and variable, but is generally greater than that of older tetracyclines. CSF penetration is poor. Tigecycline is excreted in the feces and urine predominantly as the unchanged molecule. The elimination half-life is long (37–67 h). Tigecycline clearance is decreased by 20% in patients with renal failure. No dosage adjustments are apparently necessary for tigecycline in patients with renal impairment.

• 臨床応用

  Complicated skin and skin structure infections
  Complicated intra-abdominal infections
  Community-acquired bacterial pneumonia
  Recommended principally for the treatment of infections with multiresistant organisms.

• 副作用

  Side effects typical of the group, including nausea, vomiting, diarrhea and headache, occur. Occasional cases of pancreatitis, hypoproteinemia, antibiotic-associated colitis and thrombocytopenia have also been reported.

チゲサイクリン 上流と下流の製品情報

チゲサイクリン 生産企業

Global(513)Suppliers

チゲサイクリン スペクトルデータ(¹HNMR)

220620-09-7, チゲサイクリン キーワード